SAN FRANCISCO--(BUSINESS WIRE)--
This week Invitae
Corporation (NYSE:
NVTA), a genetic information company, is participating in the
National Society of Genetic Counselors (NSGC) 35th Annual Education
Conference in Seattle, highlighting new research on genetic testing for
preventive care and new strategies for providing remote access to
genetic counseling services.
NSGC is the largest scientific session for genetic counselors. Invitae’s
presenters will discuss:
-
The role of genetic testing in guiding preventive care is an area of
keen interest for many patients and their primary clinicians. A
presentation describing a medically actionable genetic test panel
aimed at supporting prevention of disease will outline a model for how
preventive genetic testing should be provided and can yield useful
results for healthy patients (Presentation #D12-1377).
-
Interest in genetic testing continues to rise, but the number of
genetic counselors has not kept pace with demand, creating significant
challenges for patients in need of genetic counseling. Invitae’s
genetic counseling team will describe a novel model for providing
remote genetic counseling services to patients with limited access to
genetic counselors (Presentation #C04-1030).
-
Understanding the significance of genetic variants for risk of
inherited disease continues to expand, with important implications for
the diagnosis and treatment of inherited disease. The company will
present our findings on the genetic analysis of inherited pediatric
cardiomyopathy patients and how such analysis provides insight into
the significant clinical variability among all cardiomyopathy patients
(Poster #A-142).
In addition to the scientific program, the company has partnered with Genome
magazine and NSGC, supported by Global Genes and Genetic Alliance,
to establish the inaugural Code
Talker Award to recognize genetic counselors who have had a
significant impact on the lives of their patients.
“Genetic testing is quickly reshaping how clinicians diagnose, treat,
and potentially even prevent disease,” said Sean George, president and
chief operating officer at Invitae. “At Invitae, we are committed to
bringing genetics into mainstream medicine. Ensuring patients have
access to testing and genetic counseling is critical to improving and
optimizing outcomes.”
The full titles and schedule of the Invitae posters and presentations
are as follows:
-
Poster #A-142: Inherited cardiomyopathies in the pediatric population
– what molecular testing reveals | Presented by Sienna Aguilar, MS,
CGC, Invitae. 6:15 pm PDT, September 28.
-
Poster #B-290: Mammalian species conservation data and the implication
for clinical variant classification | Presented by Yuya Kobayashi,
PhD, Invitae. 5:45 pm PDT, September 29.
-
Presentation #C04-1030: A novel approach to lab-based clinical genetic
counseling | Presented by Kate Lynch, MS, LCGC, Invitae. 10:00 am PDT,
September 30.
-
Poster #C-69: Novel large rearrangement of RAD51D in an ovarian and
breast cancer family | Presented by Brittany Burnett, MS, CGC, Sharp
Healthcare in collaboration with Karen Ouyang, PhD, FACMG, Invitae.
11:30 am PDT, September 30.
-
Educational Breakout Session #D04: Bioinformatics for Genetic
Counselors 2.0: (More) Knowledge is Power | Presented by Michelle Fox,
MS, LCGC; Erica Ramos, MS, LCGC, Illumina; Eric W. Klee, PhD, Mayo
Clinic; Steve Lincoln, Invitae. 10:15 am PDT, October 1.
-
Lunch symposium: Hereditary Cancer: Current and Future Challenges.
11:45 am PDT, October 1. Presentations include:
-
The current state of genetic testing and counseling | Presented by
Andrea Forman, MS, LCGC, Fox Chase Cancer Center
-
Asking the right questions and testing your test provider |
Presented by Steve Lincoln, Invitae
-
Emerging challenges in genetic counseling | Presented by Julie
Cohen, ScM, CGC, Kennedy Krieger Institute
-
Presentation #D12-1377: Creating a medically actionable genetic
screening panel for healthy individuals | Presented by Eden
Haverfield, PhD, FACMG, Invitae. 2:15pm, PDT, October 1.
For additional information on Invitae’s presence at NSGC, please visit www.invitae.com/nsgc2016.
Additional information on the NSGC Annual Education Conference is also
available at http://nsgc.org/2016aec.
About Invitae
Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive
genetic information into mainstream medical practice to improve the
quality of healthcare for billions of people. Invitae’s goal is to
aggregate most of the world’s genetic tests into a single service with
higher quality, faster turnaround time, and lower price than many
single-gene and panel tests today. The company currently provides a
diagnostic service comprising hundreds of genes for a variety of genetic
disorders associated with oncology, cardiology, neurology, pediatrics,
and other rare disease areas. For more information, visit our website at invitae.com.
Safe Harbor Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to genetic testing and its impact on
diagnosis, treatment and prevention of disease; the company’s commitment
to bringing genetics into mainstream medicine; and that patient access
to testing and genetic counseling is critical to improving and
optimizing outcomes. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially, and
reported results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not limited
to: risks associated with the company’s ability to use rapidly changing
genetic data to interpret test results accurately and consistently; laws
and regulations applicable to the company’s business, including state
licensing requirements and potential regulation by the Food and Drug
Administration; the company’s ability to develop and commercialize new
tests and expand into new markets; and the other risks set forth in the
company’s filings with the Securities and Exchange Commission, including
the risks set forth in the company’s Quarterly Report on Form 10-Q for
the quarter ended June 30, 2016. These forward-looking statements speak
only as of the date hereof, and Invitae Corporation disclaims any
obligation to update these forward-looking statements.
NOTE: Invitae and the Invitae logo are trademarks of Invitae
Corporation. All other trademarks and service marks are the property of
their respective owners.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160928005399/en/
Source: Invitae Corporation